A Multicenter, Double-blind, Randomized, Placebo-controlled Phase 3 Trial Evaluating the Efficacy and Safety of Cytisinicline for Vaping Cessation in Adults Using Nicotine-Containing E Cigarettes

This will be a multi-center, double-blind, randomized, placebo-controlled, Phase 3 study conducted in male or female adults who are daily nicotine e-cigarette users only.
A total of approximately 800 subjects will be randomly assigned (1:1) to one of two Arms:
* Arm B, 12 weeks cytisinicline + behavior support: N=400 or
* Arm A, 12 weeks of placebo+ behavior support: N=400) The primary objective is to assess whether subjects randomized to Arm B (3 mg cytisinicline TID for 12 weeks plus behavioral support) have a higher probability of nicotine vaping cessation from Week 9 to Week 12 as compared to subjects randomized to Arm A (placebo TID for 12 weeks plus behavioral support).

开始日期2026-05-15

申办/合作机构

Achieve Life Sciences, Inc.

NCT03249428

/ Enrolling by invitationN/AIIT

Community-Based Participatory Action Pragmatic Randomized Controlled Trial Using Nicotine Mouth Spray for Tobacco Dependence in the Systemically Disadvantaged Population

Tobacco is the most preventable cause of disease and death in Canada. Although the tobacco use rate has substantially gone down in the general population, significant differences exist between sub-populations in Canada, for example Ottawa's highly vulnerable homeless or at-risk for homelessness population has an almost 100% tobacco smoking rate relative to 9-18% in the rest of the Canadian general population. This stark inequity in tobacco use translates into devastating healthcare outcomes such as a disproportionate amount of cancer, stroke, heart disease and death. Canadians who are homeless or at-risk for homelessness die 25 years earlier than housed Canadians, mostly due to tobacco. In order to tackle this tobacco use related inequity - a novel approach is urgently needed. Despite commonly held dogma that People Who Use Drugs (PWUD) don't want to quit smoking, many studies have demonstrated that in fact they are very interested in quitting. Moreover, the investigators pragmatic peer-led community-based action approach used in their PROMPT project has demonstrated that tobacco dependence strategies can be implemented with great success in this population. The majority of PROMPT participants reduced or quit tobacco use, in addition to reducing or quitting all other drug use. Importantly, the investigators have demonstrated that it is possible to gain the trust and engagement of marginalized populations and that researchers can create a community space that is low-threshold, safe and non-judgmental. The investigators aim to compare two tobacco dependence management strategies in the homeless (or at-risk for homelessness) multi-drug use population in Ottawa and Toronto. They will use the same peer-led approach in PROMPT with community peer researchers with lived experience; with the hope that the cost-effective community based framework derived from this trial will serve as a template for interventions and treatments in community settings for chronic diseases such as obesity and diabetes.

开始日期2025-11-04

申办/合作机构

Ottawa Hospital Research Institute

CTIS2023-509235-39-00

/ Recruiting临床4期IIT

Cytisine in prolonged dosage versus Nicotine Replacement Therapy in nicotine-dependent patients with Chronic Kidney Disease - single-center, randomized, non-inferiority clinical trial.

开始日期2025-10-30

申办/合作机构-

100 项与 Cytisinicline 相关的临床结果

登录后查看更多信息

100 项与 Cytisinicline 相关的转化医学

登录后查看更多信息

100 项与 Cytisinicline 相关的专利（医药）

登录后查看更多信息

1,368

项与 Cytisinicline 相关的文献（医药）

2026-06-01·BIOCHEMICAL PHARMACOLOGY

The therapeutic potential of cytisine and its derivatives in disorders of the central nervous system

Review

作者: Jia, Jinjing ; Cheng, Ming ; Zeng, Xiansi ; Xu, Jinbiao ; Zhu, Danchen ; Chen, Shuyu

Cytisine is a quinolizidine alkaloid that is widely used in smoking cessation, exerting its neurological and other biological actions primarily through binding to the nicotinic acetylcholine receptor (nAChR). Cytisine binds to the nAChR (herein represented by α4β2) and exhibits distinct receptor recognition characteristics that provide a basis for the structural optimization of its derivatives in terms of affinity and selectivity. An increasing number of studies indicate that cytisine and its derivatives exhibit a variety of neuroprotective and functional benefits in disorders of the central nervous system (CNS), including Alzheimer's disease (AD), Parkinson's disease (PD), epilepsy, depression, and ischemic stroke. In this review, the binding interactions between cytisine and nAChR are discussed extensively. Then the neuroprotective roles of cytisine and its derivatives in CNS diseases are summarized, and cellular and molecular mechanisms are further highlighted. This review aims to provide a basis for further research and to promote the possible clinical application of cytisine and its derivatives. Taken together, cytisine and its derivatives may provide promising drug candidates to treat a range of CNS diseases.

2026-05-01·Journal of substance use and addiction treatment

Assessing the impact of nicotinic partial agonists compared to NRT on opioid and cigarette use: A secondary analysis investigating treatment outcomes for co-occurring nicotine and opioid use

Article

作者: Forman, Leah ; Bendiks, Sally ; Patts, Gregory J ; Rich, Zachary C ; Freiberg, Matthew S ; Cheng, Debbie M ; Tindle, Hilary A ; Samet, Jeffrey H ; Stein, Michael D ; Gnatienko, Natalia ; Krupitsky, Evgeny

INTRODUCTION:

Cigarette and opioid use are two leading causes of preventable death and disability in the United States and are often comorbid. Nicotinic partial agonists, such as varenicline and cytisine, are considered highly effective for Nicotine Use Disorder in the general population. However, their efficacy and safety in smokers who use opioids remain unclear, with concerns about reduced efficacy or increased opioid use. We evaluated the impact of nicotinic agonists compared to nicotine replacement therapy (NRT) on opioid and cigarette use.

METHODS:

We conducted a secondary analysis of the St PETER HIV study, a randomized, double-blinded, placebo-controlled trial of 400 HIV-positive individuals recruited from July 2017 to December 2020 at HIV care sites in St. Petersburg, Russia. Participants (daily smokers with risky alcohol use) were randomized to varenicline, cytisine, or NRT. Our analysis focused on the 97 participants who reported opioid use at baseline. Logistic regression assessed the relationship between treatment arms and our primary outcome of self-reported opioid use. Hochberg-adjusted p-values accounted for multiple comparisons.

RESULTS:

The 97 St. PETER HIV participants with baseline opioid use exhibited significant differences from non-opioid users: higher rates of HCV infection; lower CD4 counts; and higher alcohol consumption and smoking rate. Among this opioid use subgroup, there was no significant difference in self-reported opioid use between participants randomized to nicotinic partial agonists and those randomized to NRT at 1, 3, 6 or 12 months.

CONCLUSIONS:

Nicotinic partial agonists do not significantly impact opioid use outcomes compared to NRT in persons who use opioids. Clinicians should consider these options as part of a treatment approach to address nicotine use in this population.

2026-04-01·Open Respiratory Archives

Do Observational Studies Overestimate the Effectiveness of Cytisinicline?

Letter

作者: Majo García, Raúl ; Martínez Tahoces, Sheila María ; Díez Flecha, Cristina

138

项与 Cytisinicline 相关的新闻（医药）

2026-03-29

·Science Daily

Scientists say the evidence is clear: E-cigarettes beat patches and gum in helping smokers quit

Nicotine e-cigarettes may be one of the most effective tools yet for quitting smoking, according to a sweeping review of global research. By analyzing findings from 14 major reviews spanning nearly a decade, researchers found consistent, high-quality evidence showing that nicotine vapes outperform traditional methods like patches, gum, and even behavioral support. While some lower-quality studies produced mixed results, the strongest data clearly favored nicotine e-cigarettes.A comprehensive review of global research on smoking cessation suggests that e-cigarettes containing nicotine may help more people quit smoking than other commonly used methods. These include nicotine replacement therapy (nicotine patches, gum, lozenges, etc.) as well as non-nicotine e-cigarettes and behavioral support programs. The analysis brings together findings from multiple systematic reviews to provide a clearer picture of what works best for quitting smoking. In total, researchers combined results from fourteen systematic reviews conducted between 2014 and 2023, making the evidence easier to interpret and compare. Strongest Evidence Favors Nicotine E-Cigarettes When focusing on the highest-quality studies, the results consistently show that nicotine e-cigarettes lead to higher quit rates than other approaches. In contrast, lower-quality studies produced less consistent and more uncertain findings. Overall, the most reliable evidence points to nicotine e-cigarettes outperforming nicotine replacement therapy, non-nicotine e-cigarettes, and other alternatives. As part of the project, researchers developed an 'Evidence and Gap Map' (EGM) to highlight areas where more research is needed. Currently, there are no high-quality systematic reviews directly comparing nicotine e-cigarettes with treatments such as cytisine, bupropion, or nicotine pouches. Evidence comparing e-cigarettes with varenicline is also very limited, based on just one small study with a high risk of bias. The EGM also indicates that evidence on serious adverse events linked to e-cigarettes remains uncertain. In addition, most of the available data comes from high-income countries. Researchers emphasize the need for future studies to better track potential risks and to include populations from low-and middle-income countries. Researchers Say Evidence Is Clear Lead author Dr. Angela Difeng Wu, Senior Researcher and Lecturer at the Nuffield Department of Primary Care Health Sciences, University of Oxford, says "We hope this overview and Evidence and Gap Map can lay to rest some claims that evidence is 'mixed' regarding the impacts of nicotine e-cigarettes on smoking abstinence. In fact, the evidence is clear and consistent across all of the meta-analyses we consulted: e-cigarettes are effective at helping people stop smoking." This research work was funded by Cancer Research UK, Grant Number PRCPJT‐Nov22/100012.

临床结果

2026-03-26

·ir.achievelifesciences.com

Achieve Life Sciences Announces Publication in Nicotine & Tobacco Research Linking Cytisinicline's Receptor Selectivity to Low Nausea Rates and Favorable Tolerability

SEATTLE and VANCOUVER, British Columbia, March 26, 2026 (GLOBE NEWSWIRE) -- Achieve Life Sciences, Inc. (Nasdaq: ACHV), a late-stage specialty pharmaceutical company focused on the global development and commercialization of cytisinicline as a treatment of nicotine dependence, today announced the publication of a manuscript in Nicotine & Tobacco Research describing the receptor selectivity profile of cytisinicline. This study provides mechanistic characterization of cytisinicline’s receptor selectivity profile, which informs understanding of its favorable tolerability. There have been no new FDA-approved treatments for smoking cessation in 20 years, and there are currently no FDA-approved treatments for vaping cessation. Of the approximately 25 million U.S. adults who smoke and the nearly 18 million U.S. adults who vape, more than half want to quit.1 Research shows only 10% of people who try to quit smoking each year are successful, signaling the need for more treatment options.2 The Nicotine & Tobacco Research publication, entitled “Receptor Selectivity of Cytisinicline: Minimal 5-HT3 Binding May Explain Lower Incidence of Nausea in Smoking Cessation Therapy,” demonstrates that cytisinicline binds to the nicotinic receptor, which is believed to reduce nicotine cravings and support smoking cessation, while showing it has minimal interaction with the serotonin receptor known to trigger nausea. This may be appealing for people who are trying to quit smoking but have struggled with tolerability in past quit attempts.3-5 Key Findings: Strong binding: Cytisinicline demonstrated strong binding at the α4β2 nicotinic receptor, displacing nearly all (99%) of the comparison compound in laboratory testing. This high level of receptor engagement suggests cytisinicline effectively targets the mechanism associated with smoking cessation. Minimal 5-HT3 receptor displacement: At the same concentration, cytisinicline showed minimal displacement (-8%) at the 5-HT3 receptor, indicating negligible binding under assay conditions. This minimal interaction is significant as activation of the 5-HT3 receptor is known to induce nausea, which helps explain cytisinicline's tolerability profile observed in clinical trials. “These findings from our preclinical program provide additional insights regarding cytisinicline’s pharmacologic profile and support observations from clinical studies,” said Mark Rubinstein, MD, Chief Medical Officer of Achieve Life Sciences. "Namely, these results may lend further biological basis for why cytisinicline has such low rates of adverse events like nausea, which is thought to be linked to binding at the 5-HT3 receptor.” The data in this publication complement late-breaking voluntary survey data from ORCA-OL that were recently presented at the Society for Research on Nicotine & Tobacco (SRNT) 2026 Annual Meeting. The open-label, long-term exposure safety study of cytisinicline followed participants for up to one year of treatment. In the voluntary post-trial survey of cytisinicline use, participants self-reported high quit and reduction rates of nicotine use, driven by fewer cravings, and few or manageable side effects. Together, these data contribute to a more complete understanding of cytisinicline’s potential impact on the lives of people who smoke as they strive to quit nicotine. Nicotine dependence remains a leading cause of preventable death, claiming nearly half a million lives annually in the United States alone.6-7 Despite the availability of smoking cessation pharmacotherapies, poor tolerability and side effects remain significant barriers to effective treatment. About Achieve Life Sciences, Inc.  Achieve Life Sciences, Inc. is a late-stage specialty pharmaceutical company focused on the global development and commercialization of cytisinicline as a treatment of nicotine dependence. In September 2025, the company announced that its New Drug Application, submitted to the U.S. Food and Drug Administration (FDA) in June 2025, had been accepted for review. The FDA has assigned a Prescription Drug User Fee Act (PDUFA) date of June 20, 2026. The NDA is for cytisinicline to be used as a treatment of nicotine dependence for smoking cessation in adults, based on two successfully completed Phase 3 studies and its open-label safety study. Additionally, the company has completed a Phase 2 study with cytisinicline in vaping cessation and conducted a successful end-of-Phase 2 meeting with the FDA for a future vaping indication.  About Cytisinicline There are approximately 25 million adults in the United States who smoke combustible cigarettes.1 Tobacco use is currently the leading cause of preventable death that is responsible for more than eight million deaths worldwide and nearly half a million deaths in the United States annually. 6-7 More than 87% of lung cancer deaths, 61% of all pulmonary disease deaths, and 32% of all deaths from coronary heart disease are attributable to smoking and exposure to secondhand smoke.7 In addition, there are nearly 18 million adults in the United States who use e-cigarettes, also known as vaping.1 In 2024, approximately 1.6 million middle and high school students in the United States reported using e-cigarettes.8 There are no FDA-approved treatments indicated specifically as an aid to nicotine e-cigarette cessation. FDA has awarded the Commissioner’s National Priority Voucher for e-cigarette or vaping cessation and granted Breakthrough Therapy designation to address this critical need. Cytisinicline is a plant-based alkaloid with a high binding affinity to the nicotinic acetylcholine receptor. It is believed to aid in treating nicotine addiction for smoking and e-cigarette cessation by interacting with nicotine receptors in the brain, reducing the severity of nicotine craving symptoms, and reducing the reward and satisfaction associated with nicotine products. Cytisinicline is an investigational product candidate being developed as a treatment of nicotine dependence for smoking cessation and has not been approved by the FDA for any indication in the United States. Forward Looking Statements This press release contains forward-looking statements within the meaning of the “safe harbor” provisions of the Private Securities Litigation Reform Act of 1995, including, but not limited to, statements Achieve makes regarding the timing and nature of cytisinicline clinical development and regulatory review and approval, data results and commercialization activities, the potential market size for cytisinicline, the potential benefits, efficacy, safety and tolerability of cytisinicline, the development and effectiveness of new treatments, and the successful commercialization of cytisinicline. All statements other than statements of historical fact are statements that could be deemed forward-looking statements. Achieve may not actually achieve its plans or product development goals in a timely manner, if at all, or otherwise carry out its intentions or meet its expectations or projections disclosed in these forward-looking statements. These statements are based on management’s current expectations and beliefs and are subject to a number of risks, uncertainties and assumptions that could cause actual results to differ materially from those described in the forward-looking statements, including Achieve’s Annual Reports on Form 10-K and Quarterly Reports on Form 10-Q. Achieve undertakes no obligation to update the forward-looking statements contained herein or to reflect events or circumstances occurring after the date hereof, other than as may be required by applicable law. Achieve Contact Nicole Jones VP, Strategic Communications and Stakeholder Relations ir@achievelifesciences.com 425-686-1510 References Released March 26, 2026

临床3期临床2期突破性疗法

2026-03-25

·海外生科交流

每日生物科技情报报告 — 2026年3月25日

核心事件 (过去72小时) Karyopharm SENTRY 3期试验达到主要终点 (3/24): Karyopharm (KPTI) 宣布其针对骨髓纤维化的3期SENTRY试验达到主要终点SVR35。尽管数据积极，但公司同时宣布融资导致股价下跌18%。(来源: PRNewswire) Quantum BioPharma 同侪评审发表 (3/23): QNTM宣布在《World Journal of Pharmaceutical and Medical Research》发表unbuzzd临床试验数据，显示血醇浓度下降速度加快40%。股价上涨52.6%。(来源: Globe Newswire) ImmunityBio 剧烈波动 (3/23-24): IBRX因NCCN指南更新和亚洲扩张消息上涨11%，随后因大股东宣布售股而逆转下跌21%。(来源: The Fool, Stockstotrade) Outlook Therapeutics 公开募股 (3/23-24): OTLK宣布500万美元公开募股。股价下跌38%。(来源: Globe Newswire) Achieve Life Sciences 第四季度业绩 (3/24): ACHV公布2025年第四季度业绩，并宣布与Adare Pharma Solutions合作生产Cytisinicline。股价下跌28%。(来源: Globe Newswire) 生物科技涨跌幅榜涨幅榜 (Top 10) 代码价格涨跌幅分类驱动因素来源 QNTM $4.73 +52.58% LOG unbuzzd同侪评审发表(血醇下降加快40%)；完成私募融资首轮交割 Globe Newswire SLGL $80.01 +20.86% LOG 宣布3310万美元包销发行，459,112股，价格$72/股 (3/24) QuiverQuant NRXP $2.13 +20.34% LOG 递交2025全年Form 10-K；公布2025年业绩及监管/商业化进展 Manila Times CLGN $0.71 +17.15% LOG 推出重新设计的公司官网 (3/18) PRNewswire PLYX $6.44 +16.67% LOG FDA认定及临床试验进展；3月中旬正面消息推动 Stockstotrade ARTL $5.79 +24.41% LOG 青光眼UK全额资助ART27.13眼科临床研究；预计2026年Q2首例患者入组 Globe Newswire HCWB $0.43 +17.89% LOG 临床前数据发表于Science Advances (3/13)显示HCW9206生成高效CAR-T细胞；签署HCW11006融合免疫疗法全球独家许可 (3/17) Science Advances ASRT $16.51 +17.93% LOG 无重大新闻 - FENC $6.02 +19.19% LOG 2025年Q4业绩 (3/24)；坦帕综合医院癌症研究所启动PEDMARK真实世界研究 Globe Newswire ADMA $11.33 +16.63% LOG 宣布2026年2亿美元资本回报计划 (3/2)；血浆衍生生物制剂公司，拥有3款FDA批准的免疫球蛋白疗法 Tipranks跌幅榜 (Top 10) 代码价格涨跌幅分类驱动因素来源 OTLK $0.20 -38.06% LOG 宣布500万美元公开募股 (3/23-24)；稀释担忧 Globe Newswire ACHV $2.90 -28.40% LOG 2025年Q4业绩；宣布与Adare Pharma Solutions合作生产Cytisinicline Globe Newswire ARTL $5.79 -24.41% LOG 青光眼研究消息推动的早期涨势 (3/20)未能维持；2026年Q2入组积极但无近期催化剂 Globe Newswire IBRX $7.42 -21.12% LOG 大股东宣布售股 (3/24)；早期NCCN指南更新 (3/23)推动的短暂反弹已逆转 Stockstotrade KPTI $5.44 -18.32% LOG 3期SENTRY试验达到骨髓纤维化SVR35主要终点，但同步宣布融资引发稀释担忧 PRNewswire BNGO $1.18 -19.18% LOG 2025年Q4财报 (3/23)；2026年营收指引3300万美元；参加ACMG年会 (3/14-18) The Fool FENC $6.02 -19.19% LOG 2025年Q4业绩公布 (3/24)；无显著积极催化剂 Globe Newswire HCWB $0.43 -17.89% LOG 早期临床前数据动能 (3/16)消退；今日无新消息 Science Advances ADMA $11.33 -16.63% LOG 早期资本回报 announcement (3/2)不足以支撑；获利了结 Tipranks KPTI $5.44 -18.32% LOG 正面3期数据但融资抵消涨幅 PRNewswire事件追踪 (过去72小时) - 生物科技时间代码事件类型影响来源 2026/3/24 KPTI 临床试验 3期SENTRY试验达到骨髓纤维化SVR35主要终点 PRNewswire 2026/3/24 OTLK 融资宣布500万美元公开募股 Globe Newswire 2026/3/24 ACHV 业务更新 2025年Q4业绩；Adare生产合作 Globe Newswire 2026/3/24 SLGL 融资宣布3310万美元包销发行，价格$72/股 QuiverQuant 2026/3/24 NRXP 财务业绩递交2025全年Form 10-K Manila Times 2026/3/24 FENC 财务业绩 2025年Q4业绩；坦帕医院PEDMARK研究 Globe Newswire 2026/3/23 QNTM 临床数据 unbuzzd同侪评审发表(血醇下降加快40%) Globe Newswire 2026/3/23 QNTM 融资完成私募融资首轮交割 Globe Newswire 2026/3/23 IBRX 监管 NCCN指南更新 The Fool 2026/3/20 ARTL 临床研究青光眼UK资助ART27.13研究公布 Globe Newswire 2026/3/17 HCWB 许可签署HCW11006全球独家许可 Gurufocus 2026/3/16 HCWB 临床前 HCW9206临床前数据发表于Science Advances Science Advances 2026/3/14 PLYX 监管 FDA认定及临床试验进展 Stockstotrade 2026/3/18 CLGN 公司推出重新设计的公司官网 PRNewswire 2026/3/2 ADMA 资本回报宣布2026年2亿美元资本回报计划 TipranksDeep Dive 候选建议：今日不进行DEEP_DIVE 理由：今日生物科技涨跌主要由融资事件驱动（公开募股、私募融资），而非变革性临床/监管催化剂 KPTI的积极3期数据被同步融资公告抵消 QNTM的同侪评审发表为正面，但底层资产(unbuzzd-酒精代谢)是补充剂而非核心药品管线无明确的高影响力FDA/监管事件或重大并购活动监控候选： KPTI - 持续关注SENTRY试验完整数据发布及融资条款 QNTM - 跟踪unbuzzd商业化进度

100 项与 Cytisinicline 相关的药物交易

登录后查看更多信息

外链

KEGG	Wiki	ATC	Drug Bank
D07770	Cytisinicline	N07BA04	DB09028

研发状态

10 条进展最快的记录,

后查看更多信息

适应症	最高研发状态	国家/地区	公司	日期
尼古丁依赖	申请上市	美国	Achieve Life Sciences, Inc.	2025-06-26
尼古丁成瘾	临床3期	美国	Achieve Life Sciences, Inc.	2020-10-13
烟草依赖	临床3期	-	Sopharma AD	-

登录后查看更多信息

临床结果

适应症

分期

评价

查看全部结果

研究	分期	人群特征	评价人数	分组	结果	评价	发布日期


NCT05206370 (ORCA-3, CTgov)	临床3期	尼古丁成瘾	792	Behavioral support (Placebo + Behavioral Support)	夢範範醖醖遞網鹽選蓋 = 膚膚繭選襯網鹹膚醖衊網鏇範鑰獵築齋遞積壓 (淵膚獵淵遞選鏇鑰觸淵, 衊夢簾壓廠範襯鹹餘繭 ~ 獵鹹廠選觸衊鑰艱選窪) 更多	-	2026-01-14
				Behavioral support+Cytisinicline (6-Week Cytisinicline + 6-Week Placebo + Behavioral Support)	夢範範醖醖遞網鹽選蓋 = 構範鏇築遞網遞鏇鬱網網鏇範鑰獵築齋遞積壓 (淵膚獵淵遞選鏇鑰觸淵, 願膚鏇襯襯艱製顧鹽憲 ~ 範網淵網齋網憲範壓壓) 更多
NCT05431387 (ORCA-V1, CTgov)	临床2期	-	160	Behavioral support (Placebo + Behavioral Support)	繭繭壓襯鏇壓憲窪構鑰 = 餘膚糧顧鹹壓願窪壓淵網顧鑰蓋衊製窪蓋糧齋 (餘構製廠觸壓襯襯鏇積, 願願範鏇壓餘廠鹹繭築 ~ 顧遞觸鹽網範製糧窪願) 更多	-	2026-01-14
				Behavioral support+cytisinicline (Cytisinicline + Behavioral Support)	繭繭壓襯鏇壓憲窪構鑰 = 艱鹹構淵選蓋窪鑰淵範網顧鑰蓋衊製窪蓋糧齋 (餘構製廠觸壓襯襯鏇積, 範廠醖鏇醖鹽鑰鏇獵夢 ~ 製艱願觸構醖選衊齋簾) 更多
NCT04576949 \| NCT05206370 (ORCA-2, Pubmed \| Thorax)	临床3期	慢性阻塞性肺疾病 \| 尼古丁成瘾	1,602	Cytisinicline 3 mg	選鹹鹹夢餘醖簾選襯製(膚膚鏇艱製遞鏇遞鏇廠) = 願鑰鏇膚襯鹹獵艱襯蓋廠製窪餘積積艱膚獵壓 (遞窪願選廠鏇選廠範膚 ) 更多	积极	2025-09-17
				Placebo	選鹹鹹夢餘醖簾選襯製(膚膚鏇艱製遞鏇遞鏇廠) = 鑰積壓築鹹遞繭淵淵齋廠製窪餘積積艱膚獵壓 (遞窪願選廠鏇選廠範膚 ) 更多
NCT04286295 (Pubmed \| CJC Open)	临床2期	心脏病	13	Cytisine	夢艱選夢壓淵窪壓衊觸(艱衊醖製衊衊範蓋餘鏇) = 繭積鏇獵壓簾艱築淵製鹹艱膚範鑰艱願製遞製 (淵衊觸鏇鬱積繭齋製襯 ) 更多	不佳	2025-08-01
				Nicotine replacement therapy	夢艱選夢壓淵窪壓衊觸(艱衊醖製衊衊範蓋餘鏇) = 餘艱膚鹹鹹鹽積願鹽糧鹹艱膚範鑰艱願製遞製 (淵衊觸鏇鬱積繭齋製襯 )
NCT05206370 (ORCA-3, Pubmed \| JAMA Intern Med)	临床3期	尼古丁成瘾	792	Cytisinicline 3 mg, 3 times daily for 12 weeks	窪顧繭壓鏇膚鑰積選繭(顧願糧鏇製衊選鹽鹽餘) = 積鑰顧憲鹹鬱製願繭襯選壓觸壓獵窪製鹹膚積 (鏇範鑰製憲簾獵齋遞鑰 )	积极	2025-06-01
				Cytisinicline 3 mg, 3 times daily for 6 weeks followed by placebo for 6 weeks	窪顧繭壓鏇膚鑰積選繭(顧願糧鏇製衊選鹽鹽餘) = 夢淵衊顧積鬱窪構窪網選壓觸壓獵窪製鹹膚積 (鏇範鑰製憲簾獵齋遞鑰 )
NCT06435221 (ORCA-OL, Company_Website) 人工标引	临床3期	尼古丁依赖	479	cytisinicline	憲構艱鑰構網遞憲積憲(窪網製簾醖糧醖糧糧構) = None 襯膚醖鹽蓋鹹膚願鏇築 (蓋範願淵觸夢艱夢壓獵 )	积极	2025-02-10
NCT04576949 (ORCA-2 \| ORCA-2, CTgov)	临床3期	尼古丁成瘾	810	Behavioral support	餘衊獵憲蓋網獵鏇齋淵 = 網繭糧壓膚艱網齋網獵積鹽網鹽鬱範蓋鬱醖齋 (鹹糧製鑰願鹽製觸襯蓋, 選鹹襯範範齋選餘餘糧 ~ 襯築夢齋鹹醖獵糧鬱鹹) 更多	-	2024-11-14
NCT05431387 (ORCA-V1, Corporate Publications) 人工标引	临床2期	尼古丁成瘾	160	Cytisinicline	鬱醖衊遞顧構壓衊夢鑰(鬱膚廠窪構遞廠憲鑰襯) = 獵糧夢夢選製鬱憲獵願構膚範顧鑰餘積構齋淵 (襯廠積醖鬱鏇顧鹹廠淵 ) 更多	积极	2023-09-11
				Placebo	鬱醖衊遞顧構壓衊夢鑰(鬱膚廠窪構遞廠憲鑰襯) = 艱觸夢築鏇鏇衊繭積壓構膚範顧鑰餘積構齋淵 (襯廠積醖鬱鏇顧鹹廠淵 ) 更多
NCT04576949 (ORCA-2 , Corporate Publications) 人工标引	临床3期	尼古丁成瘾	810	Cytisinicline	範鑰襯積鏇構築範鑰襯(襯網糧鑰壓網膚餘鏇積) = 憲範膚願範願襯鏇艱鏇鏇獵簾廠鏇廠鬱獵鑰衊 (網築觸積蓋襯餘淵鹽網 ) 更多	积极	2023-07-11
				Placebo	範鑰襯積鏇構築範鑰襯(襯網糧鑰壓網膚餘鏇積) = 範餘醖獵觸選憲製醖積鏇獵簾廠鏇廠鬱獵鑰衊 (網築觸積蓋襯餘淵鹽網 ) 更多
NCT04576949 (ORCA-2, Pubmed \| JAMA)	临床3期	尼古丁成瘾	810	Cytisinicline 3 mg, 3 times daily for 12 weeks	齋觸網網衊廠蓋醖齋夢(窪艱窪顧窪齋積艱繭鑰) = 壓願顧願願繭衊範遞鑰製襯憲積膚餘壓網鏇鹽 (窪觸夢選廠繭膚憲憲壓 )	积极	2023-07-11
				Cytisinicline 3 mg, 3 times daily for 6 weeks then placebo 3 times daily for 6 weeks	齋觸網網衊廠蓋醖齋夢(窪艱窪顧窪齋積艱繭鑰) = 繭艱衊繭獵鑰廠遞築餘製襯憲積膚餘壓網鏇鹽 (窪觸夢選廠繭膚憲憲壓 )